Novel genes associated with lymph node metastasis in triple negative breast cancer
暂无分享,去创建一个
Rodney J. Scott | John F. Forbes | J. Forbes | R. Scott | M. Wong-Brown | S. Braye | Andrea Mathe | Michelle Wong-Brown | Brianna Morten | Stephen G. Braye | Kelly A. Avery-Kiejda | K. Avery-Kiejda | B. Morten | A. Máthé | R. Scott | R. Scott
[1] E. Rassart,et al. Apolipoprotein D Inhibits Platelet-Derived Growth Factor-BB–Induced Vascular Smooth Muscle Cell Proliferated by Preventing Translocation of Phosphorylated Extracellular Signal Regulated Kinase 1/2 to the Nucleus , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[2] Natasha J. Caplen,et al. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA , 2011, Breast Cancer Research and Treatment.
[3] J. Mattick,et al. Non-coding RNA. , 2006, Human molecular genetics.
[4] Christophe Lemetre,et al. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.
[5] J. Baak,et al. Co-expression of estrogen receptor α and Apolipoprotein D in node positive operable breast cancer – possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients , 2009, Acta oncologica.
[6] Jean-Marc Guinebretière,et al. A six-gene signature predicting breast cancer lung metastasis. , 2008, Cancer research.
[7] Li Ma,et al. MicroRNA control of epithelial–mesenchymal transition and metastasis , 2012, Cancer and Metastasis Reviews.
[8] M. Duffy,et al. Targeted therapy for triple‐negative breast cancer: Where are we? , 2012, International journal of cancer.
[9] R. Lidereau,et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.
[10] L. Godsel,et al. Discriminating roles of desmosomal cadherins: beyond desmosomal adhesion. , 2007, Journal of dermatological science.
[11] T. Sørlie,et al. Triple‐negative breast cancer: Present challenges and new perspectives , 2010, Molecular oncology.
[12] R. Scott,et al. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. , 2014, Carcinogenesis.
[13] L. Carey,et al. Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.
[14] A. Haholu,et al. miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer , 2014, Journal of breast cancer.
[15] Rui Xia,et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer , 2014, Tumor Biology.
[16] S. Lakhani,et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer , 2014, Oncogenesis.
[17] John Quackenbush,et al. Confounding effects in "A six-gene signature predicting breast cancer lung metastasis". , 2009, Cancer research.
[18] A. Mackiewicz,et al. Expression of interleukin‐6, interleukin‐6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma , 2000, Cancer.
[19] Parantu K. Shah,et al. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression , 2008, Molecular systems biology.
[20] C. Croce,et al. Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancer , 2012, Molecular oncology.
[21] V. Adamo,et al. Prognostic markers in triple-negative breast cancer (TNBC): The role of androgen receptor, e-cadherin, and Ki67. , 2015 .
[22] C. R. Leemans,et al. Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice , 2004, The Journal of pathology.
[23] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[24] Soo Young Lee,et al. microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. , 2011, Experimental and therapeutic medicine.
[25] D. Jäger,et al. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. , 2001, Cancer research.
[26] Carme Camps,et al. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.
[27] Brian J. Wilson,et al. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway , 2008, Molecular Cancer.
[28] S. Narod,et al. Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[29] Shenming Wang,et al. MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer , 2014, PloS one.
[30] J. Avery. Critical review. , 2006, The Journal of the Arkansas Medical Society.
[31] P. Billon,et al. Precise deposition of histone H2A.Z in chromatin for genome expression and maintenance. , 2012, Biochimica et biophysica acta.
[32] Yiran Huang,et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. , 2013, Molecular bioSystems.
[33] R. Weinberg,et al. A Perspective on Cancer Cell Metastasis , 2011, Science.
[34] Volker Hovestadt,et al. Molecular and Cellular Pathobiology MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing , 2011 .
[35] Matthew J. Ellis,et al. Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy , 2011, International journal of breast cancer.
[36] Howard Y. Chang,et al. Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.
[37] S. Henikoff,et al. Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis. , 2010, Genome research.
[38] Sun-Mi Park,et al. The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.
[39] E. Winer,et al. Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer , 2010, Clinical Cancer Research.
[40] A. Chinnaiyan,et al. The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.
[41] F. Slack,et al. let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.
[42] Fei Chen,et al. Microprocessor of microRNAs: regulation and potential for therapeutic intervention , 2010, Molecular Cancer.
[43] G. Botti,et al. Triple negative breast cancer: from molecular portrait to therapeutic intervention. , 2010, Critical reviews in eukaryotic gene expression.
[44] S. Vacher,et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.
[45] Asli Silahtaroglu,et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.
[46] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[47] Chien-Feng Li,et al. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma , 2013, Tumor Biology.
[48] A. Nissan,et al. Multimarker RT–PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients , 2006, British Journal of Cancer.
[49] A. Levine,et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer , 2012, Proceedings of the National Academy of Sciences.
[50] Pengjun Wang,et al. Overexpression of the long non‐coding RNA MEG3 impairs in vitro glioma cell proliferation , 2012, Journal of cellular biochemistry.
[51] G. Mills,et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.
[52] A. Tutt,et al. Triple negative tumours: a critical review , 2007, Histopathology.
[53] D. Jäger,et al. The differentiation antigen NY‐BR‐1 is a potential target for antibody‐based therapies in breast cancer , 2007, International journal of cancer.
[54] R. Chacón,et al. REVIEW Triple-negative , 2022 .
[55] Z. Szallasi,et al. The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer , 2013, PloS one.
[56] J. A. Garrote-Adrados,et al. Expression and potential role of apolipoprotein D on the death–survival balance of human colorectal cancer cells under oxidative stress conditions , 2013, International Journal of Colorectal Disease.
[57] S. Hilsenbeck,et al. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency , 2013, Breast Cancer Research.
[58] R. Cress,et al. Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.
[59] J. Forbes,et al. Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer , 2014, BMC Cancer.
[60] C. Croce,et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.
[61] Leonard D. Goldstein,et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.
[62] C. Croce,et al. Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.
[63] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[64] S. Narod,et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.
[65] E. Rassart,et al. Modulation of apolipoprotein D expression and translocation under specific stress conditions. , 2007, Biochimica et biophysica acta.
[66] C. Benz,et al. Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.
[67] King-Jen Chang,et al. Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.
[68] V. Castranova,et al. Reviewof microRNAs: regulation and potential for therapeutic intervention , 2010 .
[69] Hailong Wu,et al. MicroRNA-101-mediated Akt activation and estrogen-independent growth , 2011, Oncogene.
[70] D. Jäger,et al. Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases , 2006, Clinical Cancer Research.
[71] J. Baak,et al. Biologic profiling of lymph node negative breast cancers by means of microRNA expression , 2010, Modern Pathology.
[72] M. West,et al. Gene expression predictors of breast cancer outcomes , 2003, The Lancet.
[73] R. Qin,et al. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. , 2013, Neoplasma.
[74] T. Mak,et al. ANP32E is a histone chaperone that removes H2A.Z from chromatin , 2014, Nature.
[75] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[76] M. Čížková,et al. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. , 2009, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[77] L. Holmberg,et al. Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control , 2013, BMC Genomics.
[78] L. Esserman,et al. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.